Biotech entity
pharma is the sole category represented across all 2 tracked stories. Of the tracked stories, 1 of 2 also mention Asahi Kasei, the most common co-covered peer. The 159-day window averages about 0.1 stories each week. Each story carries 2.5 original sources on average, compared with 3.7 for the broader beat in this window.
Last mentioned: Jul 27, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 2 tracked stories. Of the tracked stories, 1 of 2 also mention Asahi Kasei, the most common co-covered peer. The 159-day window averages about 0.1 stories each week. Each story carries 2.5 original sources on average, compared with 3.7 for the broader beat in this window. Their average consequence score of 6.5 runs above the beat's 6.2 for that window. We currently track 2 Biotech stories that mention Aparna Thakur, published between February 19, 2026 and July 27, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 613 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Aparna Thakur. Shared-story counts are live from our verified record — not editorial picks.
A new DelveInsight forecast projects a 47% CAGR for the Alport syndrome market through 2036, fueled by a pipeline of gene and targeted therapies. The report highlights ELX-02 from Eloxx as a potential first-mover gene therapy with an 8-week dosing interval, while big pharma players like Bayer and Novartis advance competitors.
Source: prnewswire.com · finanznachrichten.de
The global Phenylketonuria (PKU) market is projected to expand significantly through 2034, fueled by a robust pipeline of next-generation therapies and enhanced diagnostic screening. With the United States leading in diagnosed prevalence, major players like BioMarin, PTC Therapeutics, and Jnana are racing to address the metabolic limitations of current standard-of-care treatments.
Source: admin (in) · prnewswire.com
Aparna Thakur is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
